Literature DB >> 33520718

Malignant Progression Contributes to the Failure of Combination Therapy for Atypical Meningiomas.

Qing Zhang1, Zheng Wen2,3,4,5, Ming Ni2,3,4,5, Da Li2,3,4,5, Ke Wang2,3,4,5, Gui-Jun Jia2,3,4,5, Zhen Wu2,3,4,5, Li-Wei Zhang2,3,4,5, Wang Jia2,3,4,5, Liang Wang2,3,4,5, Jun-Ting Zhang2,3,4,5.   

Abstract

OBJECTIVE: To investigate the independent risk factors for recurrence in intracranial atypical meningiomas (AMs) treated with gross total resection (GTR) and early external beam radiotherapy (EBRT).
METHODS: Clinical, radiological, and pathological data of intracranial AMs treated with GTR-plus-early-EBRT between January 2008 and July 2016 were reviewed. Immunohistochemical staining for Ki-67 was performed. Kaplan-Meier curves and univariate and multivariate Cox proportional hazards regression analyses were used to explore independent predictors of tumor recurrence. Chi square test was performed to compare variables between subgroups.
RESULTS: Forty-six patients with intracranial AMs underwent GTR and early EBRT. Ten (21.7%) recurred and three (6.5%) died during a median follow-up of 76.00 months. Univariate and multivariate Cox analyses revealed that malignant progression (MP) (P = 0.009) was the only independent predictor for recurrence, while Ki-67 was of minor value in this aspect (P = 0.362). MP-AMs had a significantly higher recurrence rate (P = 0.008), a higher proportion of irregularly shaped tumors (P = 0.013) and significantly lower preoperative Karnofsky Performance Scale (KPS) scores (P = 0.040) than primary (Pri) AMs. No significant difference in Ki-67 expression was detected between these subgroups (P = 0.713).
CONCLUSIONS: MP was significantly correlated with an increased incidence of recurrence in GTR-plus-early-EBRT-treated intracranial AMs. Significantly higher frequencies of tumor relapse and irregularly shaped tumors and lower preoperative KPS scores were observed in MP-AMs compared with Pri-AMs. Ki-67 expression is of minor value in predicting tumor recurrence or distinguishing tumor origins in AMs.
Copyright © 2021 Zhang, Wen, Ni, Li, Wang, Jia, Wu, Zhang, Jia, Wang and Zhang.

Entities:  

Keywords:  Ki-67; atypical meningioma; external beam radiotherapy; gross-total resection; malignant progression

Year:  2021        PMID: 33520718      PMCID: PMC7845758          DOI: 10.3389/fonc.2020.608175

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  57 in total

Review 1.  The Ki-67 protein: from the known and the unknown.

Authors:  T Scholzen; J Gerdes
Journal:  J Cell Physiol       Date:  2000-03       Impact factor: 6.384

2.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

3.  Survival in patients treated for anaplastic meningioma.

Authors:  Jennifer Moliterno; William P Cope; Emma D Vartanian; Anne S Reiner; Roselyn Kellen; Shahiba Q Ogilvie; Jason T Huse; Philip H Gutin
Journal:  J Neurosurg       Date:  2015-04-10       Impact factor: 5.115

4.  Molecular genetic approach to human meningioma: loss of genes on chromosome 22.

Authors:  B R Seizinger; S de la Monte; L Atkins; J F Gusella; R L Martuza
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression.

Authors:  R G Weber; J Boström; M Wolter; M Baudis; V P Collins; G Reifenberger; P Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

6.  Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression.

Authors:  M Simon; A von Deimling; J J Larson; R Wellenreuther; P Kaskel; A Waha; R E Warnick; J M Tew; A G Menon
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

7.  De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome.

Authors:  Niklaus Krayenbühl; Svetlana Pravdenkova; Ossama Al-Mefty
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

Review 8.  Radiotherapy for atypical or malignant intracranial meningioma.

Authors:  M F Milosevic; P J Frost; N J Laperriere; C S Wong; W J Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

Review 9.  Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review.

Authors:  Gurvinder Kaur; Eli T Sayegh; Andrew Larson; Orin Bloch; Michelle Madden; Matthew Z Sun; Igor J Barani; C David James; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2014-04-02       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.